Control of acute transformation in chronic granulocytic leukaemia with low-dose cytosine arabinoside. 1985

J H Gallo, and R McKinley, and C S Grace, and M C Rozenberg

UI MeSH Term Description Entries
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J H Gallo, and R McKinley, and C S Grace, and M C Rozenberg
November 1985, British journal of haematology,
J H Gallo, and R McKinley, and C S Grace, and M C Rozenberg
March 1985, Scandinavian journal of haematology,
J H Gallo, and R McKinley, and C S Grace, and M C Rozenberg
April 1986, British journal of haematology,
J H Gallo, and R McKinley, and C S Grace, and M C Rozenberg
January 1971, Clinical pharmacology and therapeutics,
J H Gallo, and R McKinley, and C S Grace, and M C Rozenberg
July 1982, British journal of haematology,
J H Gallo, and R McKinley, and C S Grace, and M C Rozenberg
September 1995, European journal of haematology,
J H Gallo, and R McKinley, and C S Grace, and M C Rozenberg
August 1983, Onkologie,
J H Gallo, and R McKinley, and C S Grace, and M C Rozenberg
August 1982, Scandinavian journal of haematology,
J H Gallo, and R McKinley, and C S Grace, and M C Rozenberg
March 1997, Blood reviews,
J H Gallo, and R McKinley, and C S Grace, and M C Rozenberg
January 1987, European journal of haematology,
Copied contents to your clipboard!